healthprotocol.wiki

capitello-281_0000_rct_capitello-281-a-phase-3-study-of-capivasertib-abiraterone-vs-placebo-abiraterone-in-patients-with-pten-deficient-de-novo-metastatic-hormone-sensitive-prostate-cancer

6 findings

Protocol
medication-cancer-prostate-capivasertib-abiraterone-androgen-deprivation
Outcome
oncology-time-to-castration-resistance-months-measured
n
500
effect
25
attribution
75
Protocol
medication-cancer-prostate-capivasertib-abiraterone-androgen-deprivation
Outcome
oncology-time-to-psa-progression-months-measured
n
500
effect
15
attribution
60
Protocol
medication-cancer-prostate-capivasertib-abiraterone-androgen-deprivation
Outcome
safety-grade-3-or-higher-adverse-events-cohort-measured
n
500
effect
-30
attribution
80
Protocol
medication-cancer-prostate-capivasertib-abiraterone-androgen-deprivation
Outcome
survival-overall-proportion-cohort-measured
n
500
effect
10
attribution
60
Protocol
medication-cancer-prostate-capivasertib-abiraterone-androgen-deprivation
Outcome
survival-radiographic-progression-free-proportion-cohort-measured
n
500
effect
25
attribution
80
Protocol
medication-cancer-prostate-capivasertib-abiraterone-androgen-deprivation
Outcome
survival-symptomatic-skeletal-event-free-proportion-cohort-measured
n
500
effect
20
attribution
70